JP2010505957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505957A5 JP2010505957A5 JP2009532398A JP2009532398A JP2010505957A5 JP 2010505957 A5 JP2010505957 A5 JP 2010505957A5 JP 2009532398 A JP2009532398 A JP 2009532398A JP 2009532398 A JP2009532398 A JP 2009532398A JP 2010505957 A5 JP2010505957 A5 JP 2010505957A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound
- pharmaceutical composition
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 CC(C)NC(c1c(*)[n](-c2nc(**)c(*)cn2)nc1)=O Chemical compound CC(C)NC(c1c(*)[n](-c2nc(**)c(*)cn2)nc1)=O 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85108306P | 2006-10-10 | 2006-10-10 | |
| PCT/US2007/021678 WO2008045484A1 (en) | 2006-10-10 | 2007-10-09 | N-aryl pyrazole compounds for use against diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505957A JP2010505957A (ja) | 2010-02-25 |
| JP2010505957A5 true JP2010505957A5 (enExample) | 2010-12-16 |
Family
ID=39047570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009532398A Withdrawn JP2010505957A (ja) | 2006-10-10 | 2007-10-09 | 糖尿病に対して使用されるｎ−アリールピラゾール化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8022061B2 (enExample) |
| EP (1) | EP2079728B1 (enExample) |
| JP (1) | JP2010505957A (enExample) |
| AR (1) | AR063240A1 (enExample) |
| AU (1) | AU2007308154A1 (enExample) |
| CA (1) | CA2675511A1 (enExample) |
| CL (1) | CL2007002904A1 (enExample) |
| ES (1) | ES2430821T3 (enExample) |
| MX (1) | MX2009003821A (enExample) |
| PE (1) | PE20080858A1 (enExample) |
| TW (1) | TW200831491A (enExample) |
| WO (1) | WO2008045484A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720003A2 (pt) | 2006-12-08 | 2018-09-18 | Hoffmann La Roche | pirimidinas substituídas e seu uso como moduladores de jnk |
| CN101711245B (zh) * | 2007-07-19 | 2015-03-25 | H.隆德贝克有限公司 | 5元杂环酰胺及相关的化合物 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011146354A1 (en) * | 2010-05-20 | 2011-11-24 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP5605104B2 (ja) * | 2010-09-10 | 2014-10-15 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| JP6306607B2 (ja) | 2012-12-21 | 2018-04-04 | ケモセントリックス，インコーポレイティド | ジアゾールアミド |
| CN103772282B (zh) * | 2014-02-26 | 2015-09-23 | 上海毕得医药科技有限公司 | 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法 |
| WO2016138631A1 (en) | 2015-03-03 | 2016-09-09 | Eli Lilly And Company | Imidazo benzamide compounds |
| US9815850B2 (en) * | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| IL261998B2 (en) | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| LT3552017T (lt) | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| TWI805727B (zh) * | 2018-04-04 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 經雜芳基取代之吡唑化合物及其醫藥用途 |
| US11179371B2 (en) | 2018-07-04 | 2021-11-23 | Boehringer Ingelheim International Gmbh | Triazole benzamide derivatives as GPR142 agonists |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778433A (en) * | 1969-04-18 | 1973-12-11 | Sumitomo Chemical Co | Process for producing benzodiazepine derivatives |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JPH04145081A (ja) | 1990-10-06 | 1992-05-19 | Kumiai Chem Ind Co Ltd | ピラゾールカルボン酸誘導体及び除草剤 |
| TW312694B (enExample) | 1994-09-26 | 1997-08-11 | Daiichi Seiyaku Co | |
| US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| US6169086B1 (en) * | 1997-01-27 | 2001-01-02 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| BR9815453A (pt) | 1997-03-11 | 2001-10-23 | Du Pont | Composto, composição herbicida e método para controle do crescimento de vegetação indesejada |
| CA2408408C (en) | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
| AU2001280099A1 (en) | 2000-08-25 | 2002-04-02 | Sankyo Company Limited | 4-acylaminopyrazole derivatives |
| US20040198758A1 (en) * | 2001-08-17 | 2004-10-07 | Rapado Liliana Parra | N-heterocyclyl substituted thienyloxy-pyrimidines used as herbicides |
| AU2002363250A1 (en) * | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| DE10234876A1 (de) * | 2002-07-25 | 2004-02-05 | Bayer Cropscience Gmbh | 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine |
| JP3774184B2 (ja) | 2002-10-25 | 2006-05-10 | 株式会社フジクラ | 光ファイバ心線テープ被覆除去具及び光ファイバ心線テープ被覆除去方法 |
| EP1617840A4 (en) | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| JP2004339080A (ja) | 2003-05-13 | 2004-12-02 | Tokyo Institute Of Technology | ピラゾ−ル誘導体を含有する高血圧治療剤 |
| US6818631B1 (en) * | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| CA2551944A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2008045664A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Heterocyclic pde4 inhibitors as antiinflammatory agents |
-
2007
- 2007-10-09 WO PCT/US2007/021678 patent/WO2008045484A1/en not_active Ceased
- 2007-10-09 EP EP07839443.4A patent/EP2079728B1/en active Active
- 2007-10-09 US US11/973,900 patent/US8022061B2/en not_active Expired - Fee Related
- 2007-10-09 JP JP2009532398A patent/JP2010505957A/ja not_active Withdrawn
- 2007-10-09 MX MX2009003821A patent/MX2009003821A/es unknown
- 2007-10-09 CA CA002675511A patent/CA2675511A1/en not_active Abandoned
- 2007-10-09 ES ES07839443T patent/ES2430821T3/es active Active
- 2007-10-09 CL CL200702904A patent/CL2007002904A1/es unknown
- 2007-10-09 TW TW096137866A patent/TW200831491A/zh unknown
- 2007-10-09 AU AU2007308154A patent/AU2007308154A1/en not_active Abandoned
- 2007-10-10 PE PE2007001365A patent/PE20080858A1/es not_active Application Discontinuation
- 2007-10-10 AR ARP070104489A patent/AR063240A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2563639C2 (ru) | Замещенные соединения амида | |
| CN1826121B (zh) | 苯基与吡啶基衍生物用于制备调控钙离子释放活化钙离子通道的药物的用途 | |
| JP5749802B2 (ja) | 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ | |
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| ES2690145T3 (es) | Agonistas de GPR120 para el tratamiento de diabetes de tipo 2 | |
| EP3607821B1 (en) | Compositions, formulations and methods for treating ocular diseases | |
| JP2016534124A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| JP2012521429A (ja) | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト | |
| NZ623838A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| JP2009084270A5 (enExample) | ||
| AU2003291613B2 (en) | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | |
| CN1150185C (zh) | 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途 | |
| JP2020529440A5 (enExample) | ||
| WO2013092711A1 (en) | Trpm8 antagonists | |
| US20150299179A1 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| CN1771040A (zh) | 糖尿病治疗药 | |
| HRP20201604T1 (hr) | Sulfonamidi kao gpr40- i gpr120-agonisti | |
| CN107709332B (zh) | 一种c,o-螺环芳基糖苷类化合物及其制备和应用 | |
| RU2005106201A (ru) | Производные тиазола | |
| JP5679458B2 (ja) | 内臓脂肪重量の低下剤 | |
| RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
| ES2887011T3 (es) | Derivados de isotiazol como agonistas de GPR120 para el tratamiento de diabetes de tipo II | |
| CN102892760A (zh) | 非醇性脂肪性肝炎的预防和/或治疗剂 | |
| KR20240072145A (ko) | 트리아졸론 화합물 및 이의 의학적 용도 |